Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 107
Filter
1.
Breast Cancer Res Treat ; 65(2): 101-10, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11261825

ABSTRACT

The MCF10 series of cell lines was derived from benign breast tissue from a woman with fibrocystic disease. The MCF10 human breast epithelial model system consists of mortal MCF10M and MCF10MS (mortal cells grown in serum-free and serum-containing media, respectively), immortalized but otherwise normal MCF10F and MCF10A lines (free-floating versus growth as attached cells), transformed MCF10AneoT cells transfected with T24 Ha-ras, and premalignant MCF10AT cells with potential for neoplastic progression. The MCF10AT, derived from xenograft-passaged MCF10-AneoT cells, generates carcinomas in approximately 25% of xenografts. We now report the derivation of fully malignant MCF10CA1 lines that complete the spectrum of progression from relatively normal breast epithelial cells to breast cancer cells capable of metastasis. MCF10CA1 lines display histologic variations ranging from undifferentiated carcinomas, sometimes with focal squamous differentiation, to well-differentiated adenocarcinomas. At least two metastasize to the lung following injection of cells into the tail vein; one line grows very rapidly in the lung, with animals moribund within 4 weeks, whereas the other requires 15 weeks to reach the same endpoint. In addition to variations in efficiency of tumor production, the MCF10CA1 lines show differences in morphology in culture, anchorage-independent growth, karyotype, and immunocytochemistry profiles. The MCF10 model provides a unique tool for the investigation of molecular changes during progression of human breast neoplasia and the generation of tumor heterogeneity on a common genetic background.


Subject(s)
Breast Neoplasms/pathology , Breast/cytology , Cell Transformation, Neoplastic , Animals , Cell Transformation, Neoplastic/genetics , Female , Humans , Karyotyping , Mice , Transplantation, Heterologous , Tumor Cells, Cultured
2.
Breast Cancer Res ; 2(5): 331-4, 2000.
Article in English | MEDLINE | ID: mdl-11250725

ABSTRACT

Numerous models have been developed to address key elements in the biology of breast cancer development and progression. No model is ideal, but the most useful are those that reflect the natural history and histopathology of human disease, and allow for basic investigations into underlying cellular and molecular mechanisms. We describe two types of models: those that are directed toward early events in breast cancer development (hyperplastic alveolar nodules [HAN] murine model, MCF10AT human xenograft model); and those that seek to reflect the spectrum of metastatic disease (murine sister cell lines 67, 168, 4T07, 4T1). Collectively, these models provide cell lines that represent all of the sequential stages of progression in breast disease, which can be modified to test the effect of genetic changes.


Subject(s)
Disease Models, Animal , Mammary Neoplasms, Experimental/pathology , Female , Humans , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/metabolism
3.
Breast Cancer Res Treat ; 58(2): 183-6, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10674884

ABSTRACT

A workshop on the 'Research potential of a unique xenograft model of human proliferative breast disease' was held at the Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, in November of 1998. The accumulated information and current experimental findings on the MCF10AT model of preneoplastic, proliferative breast disease were reviewed. Discussions focused on the relevance of the model to clinical breast cancer and on the most profitable lines of further research to strengthen its utility.


Subject(s)
Breast Neoplasms/pathology , Disease Models, Animal , Mammary Neoplasms, Experimental/pathology , Animals , Female , Humans , Mice , Mice, Nude , Research Design , Tumor Cells, Cultured
4.
Int J Oncol ; 13(5): 907-15, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9772278

ABSTRACT

Utilizing the MCF10AT xenograft model for progression of human proliferative breast disease, we detected expression of the endogenous estrogen receptor (ER) gene only in MCF10AneoT and cells of the MCF10AT system, all of which stably express a transfected mutated T24 Ha-ras gene. ER transcripts were undetectable in the parental MCF10A cells and in MCF10A cells transfected with normal c-Ha-ras or vector. ER transcripts expressed in MCF10AT cells contain a normal full-length ER coding region and direct synthesis of a normally sized ER protein. The protein is functional based on its ability to mediate estradiol (E2)-induced increases of transcription from both endogenous and exogenous E2-regulated genes. Transcriptional activation of the endogenous ER gene does not appear to be related to a change in methylation status of the gene since a diagnostic CpG site in exon 1 that is methylated in ER-negative breast tumors and completely unmethylated in ER-positive breast tumors is hypomethylated to the same extent in ER-negative MCF10A cells and ER-positive MCF10AT cells. E2 increased both the number and size of soft-agar colonies formed by MCF10AT3c cells, a line from a third generation MCF10AT xenograft lesion. This suggests that xenograft passage has selected for growth regulatory pathways that are E2-responsive and that identification of these pathways and their role in progression will aid in determining how E2 acts to increase risk of breast cancer.


Subject(s)
Breast Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Receptors, Estrogen/genetics , Animals , Breast Neoplasms/metabolism , Cell Line , DNA Methylation , Disease Models, Animal , Genes, Reporter , Genes, ras/genetics , Humans , Mice , Neoplasm Transplantation , Receptors, Progesterone/biosynthesis , Receptors, Progesterone/metabolism , Transcriptional Activation , Transplantation, Heterologous , Tumor Cells, Cultured
5.
Am J Pathol ; 152(5): 1129-32, 1998 May.
Article in English | MEDLINE | ID: mdl-9588879

ABSTRACT

We have used the MCF10AT xenograft model of human proliferative breast disease to examine the early effects of estradiol exposure on morphological progression of preneoplastic lesions and to define the step(s) in the morphological sequence at which estrogen may act. The effects of estradiol on neoplastic progression of estrogen-receptor-positive MCF10AT cells in the orthotopic site were examined in ovariectomized female nude mice that received subcutaneous administration of implants of 17beta-estradiol or placebo pellets. At 10 weeks, histological analysis of the lesions derived from the estrogen-supplemented group revealed that 92% of lesions displayed histological features of atypical hyperplasia, carcinoma in situ, or invasive carcinoma, and the remaining 8% exhibited histological features of moderate hyperplasia. These highly proliferative lesions are in marked contrast to the control group in which 60% of samples displayed no evidence of hyperplasia. In contrast with control xenografts, estrogen-exposed xenografts demonstrated extensive areas of papillary growth, adenosis-like areas, prominent host inflammatory infiltration, and angiogenesis. Our results suggest that estrogen exerts a growth-promoting effect on benign or premalignant ductal epithelium by enhancing 1) the frequency of lesion formation, 2) the size of lesions, 3) the speed of transformation from normal/mild hyperplasia to those with atypia, 4) the degree of dysplasia, and 5) angiogenesis.


Subject(s)
Breast/pathology , Carcinoma in Situ/pathology , Cell Transformation, Neoplastic/pathology , Estradiol/pharmacology , Mammary Neoplasms, Experimental/pathology , Precancerous Conditions/pathology , Animals , Carcinoma in Situ/chemically induced , Cell Line , Cell Transformation, Neoplastic/chemically induced , Disease Progression , Female , Humans , Hyperplasia/chemically induced , Hyperplasia/pathology , Mammary Neoplasms, Experimental/chemically induced , Mice , Mice, Nude , Neoplasm Invasiveness , Ovariectomy , Precancerous Conditions/chemically induced , Transplantation, Heterologous
6.
Int Rev Cytol ; 177: 1-56, 1998.
Article in English | MEDLINE | ID: mdl-9378615

ABSTRACT

Variability in disease presentation and course is a hallmark of cancer. Variability is seen among similarly diagnosed cancers in different patients or animal hosts and in the same cancer at different periods of time. This latter type of variability, termed "tumor progression," was defined by Foulds in a series of six rules that describe the independent behavior of individual cancers and the independent evolution of different cancer characteristics. Tumor progression is believed to result from variability among subpopulations of tumor cells within individual cancers and from selection of these subpopulations by conditions within the cancer environment, such that different subpopulations come to prominence over the course of cancer development and growth. Interactions among subpopulations, however, modulate tumor behavior as well as tumor evolution. The leading hypothesis for the origin of tumor subpopulations is the genetic instability of cancer cells. There are a number of possible mechanisms of genetic instability, some internal to cancer cells (mutation, amplification, mutator phenotypes, DNA repair deficiencies) and some present in the tumor microenvironment (endogenous mutagens). There are also potential epigenetic mechanisms of variability, including alterations in gene regulation, differentiation, adaptation, and cell fusion. Regardless of mechanism, the heterogeneity of tumor subpopulations poses a number of challenges to the practice of cancer research, including the design of reproducible and meaningful experiments. Tumor heterogeneity also has significant consequences for the clinical assessment of tumor prognosis and the development of effective treatment regimens.


Subject(s)
Gene Expression Regulation, Neoplastic , Neoplasms, Experimental/genetics , Neoplasms, Experimental/pathology , Neoplasms/genetics , Neoplasms/pathology , Animals , Humans , Neoplasms/physiopathology , Neoplasms, Experimental/physiopathology
7.
FASEB J ; 11(7): 535-43, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9212077

ABSTRACT

Research in breast cancer extends in many directions, stimulated by concerns related to the high incidence of the disease and the relative unpredictability of its clinical course. Examples of work in several directions are presented here arranged by four levels of analysis. 1) Molecular, intracellular events (molecular genetics). Recent identification of genes that predispose to breast cancer, and the isolation of those genes and their protein products, permit investigations of the most critical issues: the roles of these genes in normal development and breast differentiation, and how their alteration permits or contributes to tumor initiation. Thus, we expect that understanding the functions of the genes involved in inherited susceptibility to breast cancer will also be informative for sporadic breast cancers. 2) Cellular biology (cellular models for preneoplastic disease). We examine models of breast cancer development and ask how they help to validate a morphologic sequence for human breast neoplasia and whether they permit investigation of how to modify disease progression. Two useful models, one in transgenic mice and the other using human breast stem cells capable of culture and xenograft growth, are now available. 3) Tissue and organ (the tumor and its local environment). We look at the relationship of the tumor cell population to its local environment (stroma, blood vessels, etc.). This leads naturally to questions of how neighboring tissues and cytokines may modify tumor growth. 4) The individual as an organism and member of a population (hormonal rise and chemoprevention). We address identification of the primarily hormonal risk factors and a possible related mode of cancer prevention.


Subject(s)
Breast Neoplasms , Animals , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/prevention & control , Chemoprevention , Disease Models, Animal , Female , Humans , Mice , Research
8.
Parasitology ; 115 Suppl: S141-53, 1997.
Article in English | MEDLINE | ID: mdl-9571699

ABSTRACT

Breast cancer is a complex disease. Its aetiology is multifactorial, its period of development can span decades, and its clinical course is highly variable. Evaluation of the role of the immune response in either the development or control of breast cancer is also complex. Nevertheless, there is substantial information that in this disease, the immune response is not a host defence reaction and may even serve to facilitate cancer development. This evidence comes from a variety of sources including clinical-pathological investigations in women that show a correlation between the intensity of lymphocytic infiltration into the tumour mass with poor prognosis, studies in breast cancer patients that demonstrate a similar correlation between delayed hypersensitivity reactivity or in vitro assays of immune reactivity to tumour cell membranes or non-specific antigens and poor prognosis, and analyses of cancer incidence in chronically immunosuppressed, kidney transplant recipients who develop an unexpectedly low incidence of breast cancer. The overall conclusions from these human studies are corroborated by observations in mouse mammary tumour models that also demonstrate immune enhancement of breast cell proliferation in vitro and of breast cancer development in vivo. Potential mechanisms for these effects include production, by inflammatory cell infiltrates, of direct or indirect modulators of breast cell growth, e.g. cytokines, peptide or steroid hormones, enzymes involved in steroid metabolism, as well as of antibodies to growth factors or their receptors. These immune facilitatory mechanisms must be overcome if immune-based therapies are to be applied successfully in breast cancer.


Subject(s)
Breast Neoplasms/immunology , Animals , Breast Neoplasms/pathology , Disease Progression , Female , Humans , Hypersensitivity, Delayed , Immune Tolerance , Immunity, Cellular , Immunocompetence , Mammary Neoplasms, Experimental/immunology , Mice
9.
Am J Pathol ; 148(1): 313-9, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8546221

ABSTRACT

A human cell line (MCF10A) originated from spontaneous immortalization of breast epithelial cells obtained from a patient with fibrocystic disease. MCF10A cells do not survive in vivo in immunodeficient mice. However, T24 c-Ha-ras oncogene-transfected MCF10A cells (MCF10AT) form small nodules in nude/beige mice that persist for at least 1 year and sporadically progress to carcinomas. By reestablishing cells in tissue culture from one of the carcinomas, a cell line designated MCF10AT1 was derived that forms simple ducts when transplanted in Matrigel into immunodeficient mice. With time in vivo, the epithelium becomes proliferative and a cribriform pattern develops within the xenografts. A significant number progress to lesions resembling atypical hyperplasia and carcinoma in situ in women, and approximately 25% progress to invasive carcinomas with various types of differentiation including glandular, squamous, and undifferentiated. Cells have been established in culture from lesions representing successive transplant generations. With each generation, cells are somewhat more likely to progress to high risk lesions resembling human proliferative breast disease. Although the incidence of invasive carcinoma remained fairly constant at 20 to 25%, the frequency of nodules showing proliferative breast disease rose from 23% in the first transplant generation to 56% in the fourth transplant generation.


Subject(s)
Breast Neoplasms/pathology , Breast/pathology , Carcinoma in Situ/pathology , Carcinoma/pathology , Fibrocystic Breast Disease/pathology , Precancerous Conditions/pathology , Animals , Cell Line , Disease Models, Animal , Female , Humans , Hyperplasia/pathology , Mice , Mice, Nude , Time Factors
11.
J Exp Ther Oncol ; 1(1): 30-8, 1996 Jan.
Article in English | MEDLINE | ID: mdl-9414386

ABSTRACT

Our previous studies have indicated that the expression by tumor cells of sensitivity to chemotherapeutic drugs such as methotrexate can be affected by the presence of other tumor cells; thus, otherwise methotrexate-resistant cells may respond to that drug in the presence of methotrexate-sensitive cells. In order to determine whether tumor heterogeneity also affects the emergence of drug resistance, we measured the rate of development of methotrexate resistance in mixed monolayer cultures of three mammary tumor subpopulation lines (66, 168TFAR, 4T07) that differ in degree of sensitivity to methotrexate. Cultures were treated weekly with 80 nM or 200 nM methotrexate. Each individual cell line was re-isolated from the mixture by passage in selective medium and then assayed for methotrexate sensitivity. Cultures of each of the three lines were treated and assayed in parallel. Few differences in the rate of development of methotrexate resistance were seen among cells from mixtures and cells cultured alone; line 4T07 appeared to become resistant somewhat more rapidly in mixtures. In untreated mixed cultures, line 66, the line least sensitive to methotrexate, gradually became dominant; this process was accelerated in treated cultures. One methotrexate-resistant subline from each parent cell line was tested to determine the mechanisms by which methotrexate resistance was increased. Two lines appeared to have increased levels of dihydrofolate reductase, and one exhibited decreased methotrexate transport as well. The third cell line had neither mechanism. Others have shown that tumor heterogeneity can act as a brake on the rate of development of new metastatic or immunogenic variants. Our data indicate that, at least in the model system we have tested, the rate of development of extrinsic drug resistance is substantially independent of pre-existing clonal diversity.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Drug Resistance, Neoplasm/physiology , Mammary Neoplasms, Experimental/drug therapy , Methotrexate/pharmacology , Animals , Antimetabolites, Antineoplastic/metabolism , Mammary Neoplasms, Experimental/metabolism , Methotrexate/metabolism , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Neoplastic Stem Cells , Tetrahydrofolate Dehydrogenase/metabolism
12.
Cancer Immunol Immunother ; 39(5): 291-8, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7987860

ABSTRACT

We have previously shown that the immunoregulatory function of prolactin may play a role in the progression of the mouse mammary preneoplastic hyperplastic alveolar nodule (HAN) line C4 to carcinoma. In this study we investigated the direct effect of prolactin on lymphocytes isolated from normal and C4-HAN-bearing mice. In addition, we tested the effect of ovariectomy on prolactin/lymphocyte interaction to see whether, as has been reported in rats [Mukherjee P., Hymer W. C. (1992) Prog Neuroendocrinol Immunol 5: 108; Viselli S. M. et al. (1991) Endocrinology 129: 983], removal of estrogen would enhance the response to prolactin in mice. Proliferation of splenocytes, lymph node cells and HAN-infiltrating lymphocytes was stimulated by prolactin in a dose-responsive fashion. Ovariectomy did not alter this effect consistently. Cell-cycle analysis based on simultaneous staining of DNA and RNA revealed that prolactin-stimulated lymphocytes progress through all phases of the cell cycle whereas anti-prolactin antiserum inhibits this stimulation. Two-color flow-cytometric analysis revealed the time-dependent induction of interleukin-2 (IL-2) receptor expression on both CD4+ and CD8+ cells by prolactin. Prolactin-treated lymphocytes also produced low yet detectable levels of bioactive IL-2 in a dose- and time-dependent fashion. Prolactin enhanced lymphocyte responsiveness to mitogens and showed a marked synergism at suboptimal concentrations. Pretreatment of splenocytes from HAN bearers with a high concentration of prolactin slightly enhanced natural killer (NK) activity; anti-prolactin antiserum reduced the NK lytic activity of poly(I).poly(C)-activated splenocytes from HAN-bearing mice. Our results provide direct experimental evidence for the stimulatory effect of prolactin on lymphocyte function and IL-2-mediated lymphocyte proliferation and suggest a mechanism linking the endocrine system to immunomediated enhancement of HAN progression.


Subject(s)
Lymphocyte Activation/drug effects , Mammary Neoplasms, Experimental/immunology , Precancerous Conditions/immunology , Prolactin/pharmacology , Animals , Cell Cycle , Female , Interleukin-2/biosynthesis , Mice , Mice, Inbred BALB C , Receptors, Interleukin-2/biosynthesis , T-Lymphocytes/immunology
13.
Genes Chromosomes Cancer ; 10(1): 59-65, 1994 May.
Article in English | MEDLINE | ID: mdl-7519875

ABSTRACT

We describe a series of five immortal breast cell lines that have emerged independently from diploid cultures from two individuals. We have karyotyped representative cultures of each of these lines prior to and at intervals after immortalization. Although considerable diversity of chromosomal aberration was found among the five lines, analysis of sublines has defined the chromosomal changes common for each immortalization. These changes differed both within and between the individual patient sources. Some common alterations were noted in lines from both patients, however, including loss of the short arm of chromosome 20 and gain of 1q. We suggest that genes within these chromosomal regions contribute to spontaneous immortalization of human breast epithelium.


Subject(s)
Breast Neoplasms/genetics , Breast/pathology , Cell Transformation, Neoplastic/genetics , Genetic Markers , Adult , Breast Neoplasms/pathology , Chromosome Aberrations , Epithelium/pathology , Female , Humans , Karyotyping , Tumor Cells, Cultured
14.
J Natl Cancer Inst ; 85(21): 1725-32, 1993 Nov 03.
Article in English | MEDLINE | ID: mdl-8411256

ABSTRACT

BACKGROUND: Progression of proliferative breast disease has been associated with increased risk for development of invasive carcinoma. Cell lines have been developed to facilitate the study of this process. Human cell line MCF10A originated from spontaneous immortalization of breast epithelial cells obtained from a patient with fibrocystic disease, and cell lines MCF10AneoN and MCF10AneoT were created by stable transfection of these cells with the neomycin-resistance gene and either the HRAS gene or the mutated T-24 HRAS gene, respectively. PURPOSE: Our goal was to develop an experimental model of progressive human proliferative breast disease. METHODS: MCF10A, MCF10AneoN, and MCF10AneoT cells were injected subcutaneously into the dorsal flank of male nude/beige (C57/BALB/c nu/nu bg/bg) mice (12 mice for each cell type). These mice were examined periodically for formation and persistence or growth of palpable nodules. One mouse per group was killed 1 week after cell injection; thereafter, mice were observed as long as possible. Cells were recovered from palpable lesions by enzymatic dissociation of the excised lesions. Cells re-established in tissue culture from a week-14 tumor (MCF10AneoT.TG1) were injected into 12 male nude/beige mice. Southern blot hybridization analysis of the HRAS gene locus and cytogenetic analyses were performed. RESULTS: Transplanted MCF10A and MCF10AneoN cells formed transient, small palpable nodules that regressed and disappeared during the 4th and 5th weeks. In 10 of the 12 mice, T-24 HRAS gene-transfected MCF10A cells (MCF10AneoT) formed small, flat nodules that persisted for at least 1 year. Three of these xenografts became carcinomas. One (removed 7 weeks after transplantation) was an undifferentiated carcinoma composed of polygonal cells with large, vesicular nuclei and numerous mitoses. The second (removed after 14 weeks) was an invasive squamous cell carcinoma. The third (removed after 56 weeks) was a moderately differentiated adenocarcinoma. Initially, xenografts of MCF10AneoT.TG1 cells showed intraductal proliferative changes; after 23 weeks, the lesions showed histologic features resembling those seen in atypical hyperplasia of the human breast, and later lesions showed characteristics of carcinoma in situ. The MCF10 lineage of cells of three MCF10AneoT.TG1 xenografts was confirmed by DNA fingerprinting and karyotype analysis. CONCLUSIONS: MCF10AneoT and MCF10AneoT.TG1 comprise a transplantable xenograft model that produces a broad spectrum of human proliferative breast disease. IMPLICATIONS: The reproducible establishment of representative stages in early breast cancer progression from the MCF10 model offers a new opportunity to analyze critical events of carcinogenesis and progression in breast cancer.


Subject(s)
Breast Diseases/pathology , Cell Transformation, Neoplastic/pathology , Adult , Animals , Blotting, Southern , Breast Diseases/genetics , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Line, Transformed , Cell Transformation, Neoplastic/genetics , DNA Fingerprinting , Female , Fibrocystic Breast Disease/pathology , Humans , Karyotyping , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Nude , Models, Biological , Transplantation, Heterologous
16.
Br J Cancer ; 68(1): 18-25, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8318410

ABSTRACT

In order to examine in detail the sensitivity to chemotherapy of tumour cells at various organ sites and at various stages of metastasis, we have used a series of cell lines, all selected from sister subpopulations derived from a single mouse mammary tumour, which can be distinguished and quantitated from normal cells and from each other through growth in selective medium. For the studies described here, we used two lines, 4T07 and 66FAR, which will form colonies in vitro in medium containing 60 microM 6-thioguanine or 330 microM 2,6-diaminopurine, respectively. Both cell lines have similar sensitivity to the test chemotherapeutic agent, melphalan, in vitro. These two tumour cell lines were treated with melphalan in vivo, when growing either in lungs as experimental metastases at various times after cell injection or as palpable tumours growing subcutaneously. Responses to various doses of melphalan were measured by removing lungs or subcutaneous tumours and performing colony-forming assays in selective medium. The data indicate marked shifts in sensitivity as a function of metastatic stage. Analyses of dose-response curves show that both cell lines were similarly sensitive to melphalan at early times (45 min) after cell injection i.v. but became less sensitive at an intermediate time after injection (3 days). Differences between the two lines became apparent at later times after i.v. injection (by day 8 or 9) and in subcutaneous tumours, where a marked reduction in the shoulder of the dose response curve was seen in line 4T07, resulting in sensitivity equal to or greater than the of early times, whereas the dose response parameters of 66FAR remained at those of the intermediate time point. These results show that, in heterogeneous tumours, individual subpopulations of tumour cells may respond differently to chemotherapeutic agents at various disease stages. In vitro measures of tumour sensitivity do not predict these changes in in vivo sensitivity. Model systems similar to the one described here may yield information which will eventually be useful in maximising the efficacy of clinically relevant adjuvant chemotherapy regimens.


Subject(s)
Lung Neoplasms/secondary , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/pathology , Melphalan/toxicity , Melphalan/therapeutic use , Neoplasm Metastasis/pathology , Skin Neoplasms/secondary , Animals , Cell Division/drug effects , Dose-Response Relationship, Drug , Female , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Male , Mice , Mice, Inbred BALB C , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Tumor Cells, Cultured , Tumor Stem Cell Assay
17.
Stem Cells ; 11(3): 199-203, 1993 May.
Article in English | MEDLINE | ID: mdl-8318906

ABSTRACT

It is now well accepted that cancers are heterogeneous and contain multiple subpopulations of cancer cells that differ in important behavioral properties, such as growth rate, ability to metastasize and sensitivity to treatment. This review describes results using a mouse mammary tumor system to model the effect of heterogeneity on tumor growth and response to chemotherapy. Tumor subpopulations that differ in growth and therapy parameters are mixed together to simulate tumor heterogeneity. The mixtures are studied in a variety of protocols designed to detect interactions between the subpopulations and to determine the mechanisms of these interactions. The central conclusion of this work is that tumor subpopulations do not behave independently of each other but rather form a society of cells in which they influence each other's growth and treatment response. The mechanisms by which they do so depend on the unique characteristics of the interacting subpopulations, on the behavior being affected and on the circumstances of their interaction. These observations suggest that the maintenance of tumor heterogeneity is a consequence of the cancer cell society and that cancer behavior and progression depend on interactions among all the members of that society, not just on its most deviant variants.


Subject(s)
Mammary Neoplasms, Experimental/pathology , Animals , Mammary Neoplasms, Experimental/drug therapy , Mice
18.
J Natl Cancer Inst ; 85(7): 546-53, 1993 Apr 07.
Article in English | MEDLINE | ID: mdl-8455201

ABSTRACT

BACKGROUND: Tumor cell-targeted cytokine gene transfer has been used to generate tumor cell vaccines, but this approach is limited by the need to establish and implant live tumor cells. PURPOSE: The purpose of this study was to determine if stromal fibroblasts could be used as an alternative vehicle for delivery of the cytokine interleukin-2 (IL-2) into the tumor microenvironment. We attempted to establish the feasibility of (a) genetic immunotherapy in a mammary tumor system and (b) engineering stromal fibroblasts as well as tumor cells. We compared the effects of tumor cell-mediated and stromal fibroblast-mediated local IL-2 expression on the generation of antitumor immune responses. METHODS: Retroviral vectors containing a human IL-2 gene were used to transduce a mouse mammary tumor line, 4TO7, and an immortalized but nontumorigenic fibroblast line established from syngeneic mammary fatpads. Expression of the IL-2 gene in transduced cells was determined by measuring IL-2 secretion, by RNA-polymerase chain reaction, and by immunochemistry. Groups of 5-12 BALB/c mice were injected with either 4TO7 cells or various doses of IL-2-secreting 4TO7 cells (4TO7-IL-2); tumor growth was monitored. To test whether local IL-2 expression by transduced cells could influence the growth of unmodified tumor cells, we determined tumor development in groups of mice treated with 4TO7 cells co-injected with either 4TO7-IL-2 cells or IL-2-secreting fibroblasts. RESULTS: 4TO7-IL-2 cells induced active immunity able to reject the immunizing tumor and to resist challenge with parental 4TO7 cells on the contralateral side. Mice pretreated with 4TO7-IL-2 were significantly protected compared with untreated control animals or mice pretreated with irradiated 4TO7 cells. The immunity induced by 4TO7-IL-2 cells did not protect against challenge with another subline, 4T1, which was derived from the same spontaneously arising mammary tumor as 4TO7. Co-injection of 4TO7 cells with 4TO7-IL-2 cells reduced tumorigenicity, whereas co-injection of 4TO7 cells with IL-2 secreting fibroblasts did not. CONCLUSION: Our results suggest that induction of anti-tumor immune response by local IL-2 production is most effective when the helper cytokine is secreted by the tumor cell. IMPLICATION: Our studies caution against the use of IL-2 gene-transduced syngeneic stromal cells as an alternative strategy of gene therapy for cancer. However, they may allow study of the mechanisms of tumor antigen recognition and the possible involvement of co-stimulatory signals for effective tumor vaccination by gene-modified cells.


Subject(s)
Fibroblasts/immunology , Interleukin-2/genetics , Mammary Neoplasms, Experimental/immunology , Animals , Base Sequence , Cells, Cultured , Feasibility Studies , Female , Fibroblasts/transplantation , Genetic Vectors , Immunotherapy/methods , Mammary Glands, Animal/cytology , Mammary Neoplasms, Experimental/genetics , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Retroviridae/genetics , Transduction, Genetic , Transfection/methods , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...